Trials / Completed
CompletedNCT04624217
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
A Phase Ib/II Trial of SHR-1701 Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Subjects With Advanced/Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and determine the RP2D for SHR-1701 in the combined regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | PDL1/TGFβ |
Timeline
- Start date
- 2020-11-24
- Primary completion
- 2021-09-16
- Completion
- 2023-02-08
- First posted
- 2020-11-10
- Last updated
- 2024-01-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04624217. Inclusion in this directory is not an endorsement.